Identification

Name
Cinnarizine
Accession Number
DB00568  (APRD00332)
Type
Small Molecule
Groups
Approved, Investigational
Description

Cinnarizine is an anti-histaminic drug which is mainly used for the control of vomiting due to motion sickness. Cinnarizine was first synthesized by Janssen Pharmaceutica in 1955.

It acts by interfering with the signal transmission between vestibular apparatus of the inner ear and the vomiting centre of the hypothalamus. The disparity of signal processing between inner ear motion receptors and the visual senses is abolished, so that the confusion of brain whether the individual is moving or standing is reduced. Vomiting in motion sickness is actually a physiological compensatory mechanism of the brain to keep the individual from moving so that it can adjust to the signal perception.

Cinnarizine could be also viewed as a nootropic drug because of its vasorelaxating abilities (due to calcium channel blockage), which happen mostly in brain. It is also effectively combined with other nootropics, primarily piracetam; in such combination each drug potentiate the other in boosting brain oxygen supply.

Structure
Thumb
Synonyms
  • 1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine
  • 1-Benzhydryl-4-cinnamylpiperazin
  • 1-Cinnamyl-4-(diphenylmethyl)piperazine
  • Cinarizina
  • Cinnarizine
  • Cinnarizinum
External IDs
5-23-01-00233 / 516 MD / 516-MD / BRN 0626121 / R 1575 / R 516 / UNII-3DI2E1X18L
Product Ingredients
IngredientUNIICASInChI Key
Cinnarizine hydrochloride5AKM4OA6VO25332-14-3LYXJDKBTSDYXQV-RSGUCCNWSA-N
International/Other Brands
Cinazyn (Italchimici) / Cinnageron (Streuli Pharma) / Folcodal (Ivax) / Sepan (Janssen-Cilag) / Stugeron (Janssen) / Stugeron Forte (Janssen) / Toliman (Scharper)
Categories
UNII
3DI2E1X18L
CAS number
298-57-7
Weight
Average: 368.5139
Monoisotopic: 368.225248906
Chemical Formula
C26H28N2
InChI Key
DERZBLKQOCDDDZ-JLHYYAGUSA-N
InChI
InChI=1S/C26H28N2/c1-4-11-23(12-5-1)13-10-18-27-19-21-28(22-20-27)26(24-14-6-2-7-15-24)25-16-8-3-9-17-25/h1-17,26H,18-22H2/b13-10+
IUPAC Name
1-(diphenylmethyl)-4-(3-phenylprop-2-en-1-yl)piperazine
SMILES
C(C=CC1=CC=CC=C1)N1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of vertigo/meniere's disease, nausea and vomiting, motion sickness and also useful for vestibular symptoms of other origins.

Pharmacodynamics

Cinnarizine is an antihistamine and a calcium channel blocker. Histamines mediate a number of activities such as contraction of smooth muscle of the airways and gastrointestinal tract, vasodilatation, cardiac stimulation, secretion of gastric acid, promotion of interleukin release and chemotaxis of eosinophils and mast cells. Competitive antagonists at histamine H1 receptors may be divided into first (sedating) and second (non-sedating) generation agents. Some, such as Cinnarizine also block muscarinic acetylcholine receptors and are used as anti-emetic agents. Cinnarizine through its calcium channel blocking ability also inhibits stimulation of the vestibular system.

Mechanism of action

Cinnarizine inhibits contractions of vascular smooth muscle cells by blocking L-type and T-type voltage gated calcium channels. Cinnarizine has also been implicated in binding to dopamine D2 receptors, histamine H1 receptors, and muscarinic acetylcholine receptors.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
AVoltage-dependent L-type calcium channel subunit alpha-1C
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1D
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1F
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1S
inhibitor
Human
AVoltage-dependent T-type calcium channel subunit alpha-1G
inhibitor
Human
AVoltage-dependent T-type calcium channel subunit alpha-1H
inhibitor
Human
AVoltage-dependent T-type calcium channel subunit alpha-1I
inhibitor
Human
ND(2) dopamine receptor
other/unknown
Human
UD(1) dopamine receptor
binder
Human
UMuscarinic acetylcholine receptor
binder
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Cinnarizine H1-Antihistamine ActionDrug action
Cinnarizine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Cinnarizine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative and stimulatory activities of Cinnarizine.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative and stimulatory activities of Cinnarizine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative and stimulatory activities of Cinnarizine.Experimental, Illicit
AbafunginThe therapeutic efficacy of Abafungin can be increased when used in combination with Cinnarizine.Investigational
AbexinostatThe risk or severity of QTc prolongation can be increased when Abexinostat is combined with Cinnarizine.Investigational
AbirateroneThe serum concentration of Cinnarizine can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Cinnarizine.Approved, Vet Approved
AceprometazineThe risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Cinnarizine.Approved
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Cinnarizine.Approved
AlbaconazoleThe therapeutic efficacy of Albaconazole can be increased when used in combination with Cinnarizine.Investigational
AlcaftadineThe risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Cinnarizine.Approved
AlcuroniumCinnarizine may increase the neuromuscular blocking activities of Alcuronium.Experimental
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Cinnarizine.Approved, Investigational
AlimemazineThe risk or severity of QTc prolongation can be increased when Alimemazine is combined with Cinnarizine.Approved, Vet Approved
AlosetronThe metabolism of Cinnarizine can be decreased when combined with Alosetron.Approved, Withdrawn
AmantadineThe risk or severity of QTc prolongation can be increased when Amantadine is combined with Cinnarizine.Approved
AmifampridineThe risk or severity of QTc prolongation can be increased when Amifampridine is combined with Cinnarizine.Approved
AmiodaroneThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Amiodarone.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Cinnarizine.Approved
AmobarbitalThe metabolism of Cinnarizine can be increased when combined with Amobarbital.Approved, Illicit
AmodiaquineThe risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Cinnarizine.Approved, Investigational
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Cinnarizine.Approved
AmphetamineAmphetamine may decrease the sedative and stimulatory activities of Cinnarizine.Approved, Illicit, Investigational
Amphotericin BCinnarizine may decrease the nephrotoxic activities of Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Cinnarizine can be decreased when combined with Amprenavir.Approved, Investigational
AnagrelideThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Anagrelide.Approved
AntazolineThe risk or severity of QTc prolongation can be increased when Antazoline is combined with Cinnarizine.Approved
ApalutamideThe serum concentration of Cinnarizine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineThe risk or severity of QTc prolongation can be increased when Apomorphine is combined with Cinnarizine.Approved, Investigational
AprepitantThe serum concentration of Cinnarizine can be increased when it is combined with Aprepitant.Approved, Investigational
ArformoterolThe risk or severity of QTc prolongation can be increased when Arformoterol is combined with Cinnarizine.Approved, Investigational
AripiprazoleThe risk or severity of hypotension can be increased when Aripiprazole is combined with Cinnarizine.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Cinnarizine.Approved, Investigational
ArotinololThe risk or severity of hypotension can be increased when Arotinolol is combined with Cinnarizine.Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Artemether.Approved
AsenapineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Asenapine.Approved
AstemizoleThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Astemizole.Approved, Withdrawn
AtazanavirThe risk or severity of QTc prolongation can be increased when Atazanavir is combined with Cinnarizine.Approved, Investigational
AtomoxetineThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Cinnarizine.Approved
AtracuriumCinnarizine may increase the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateCinnarizine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzatadineThe risk or severity of QTc prolongation can be increased when Azatadine is combined with Cinnarizine.Approved
AzelastineThe risk or severity of QTc prolongation can be increased when Azelastine is combined with Cinnarizine.Approved
AzithromycinThe risk or severity of QTc prolongation can be increased when Azithromycin is combined with Cinnarizine.Approved
BarbexacloneThe metabolism of Cinnarizine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Cinnarizine can be increased when combined with Barbital.Illicit
BedaquilineThe risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Cinnarizine.Approved
BenzatropineThe risk or severity of QTc prolongation can be increased when Benzatropine is combined with Cinnarizine.Approved
BenzphetamineBenzphetamine may decrease the sedative and stimulatory activities of Cinnarizine.Approved, Illicit
Benzylpenicilloyl PolylysineCinnarizine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Bepridil.Approved, Withdrawn
BesifloxacinThe risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Cinnarizine.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Cinnarizine.Approved, Investigational
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Cinnarizine.Approved
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Cinnarizine.Approved, Investigational
BilastineThe risk or severity of QTc prolongation can be increased when Bilastine is combined with Cinnarizine.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Cinnarizine.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Cinnarizine.Approved
BoceprevirThe metabolism of Cinnarizine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of QTc prolongation can be increased when Bortezomib is combined with Cinnarizine.Approved, Investigational
BosentanThe serum concentration of Cinnarizine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Cinnarizine.Approved, Investigational
BromocriptineThe risk or severity of hypotension can be increased when Bromocriptine is combined with Cinnarizine.Approved, Investigational
BrompheniramineThe risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Cinnarizine.Approved
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Cinnarizine.Investigational
BuclizineThe risk or severity of QTc prolongation can be increased when Buclizine is combined with Cinnarizine.Approved
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Cinnarizine.Investigational
BuserelinThe risk or severity of QTc prolongation can be increased when Buserelin is combined with Cinnarizine.Approved, Investigational
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Cinnarizine.Approved
ButriptylineThe risk or severity of QTc prolongation can be increased when Butriptyline is combined with Cinnarizine.Approved
CaffeineThe metabolism of Cinnarizine can be decreased when combined with Caffeine.Approved
Calcium AcetateThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Calcium Phosphate.Approved
CarbamazepineThe metabolism of Cinnarizine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Cinnarizine.Approved
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Cinnarizine.Approved, Investigational
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Cinnarizine.Approved, Investigational
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Cinnarizine.Approved, Investigational, Nutraceutical, Vet Approved
CeritinibThe serum concentration of Cinnarizine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of QTc prolongation can be increased when Cetirizine is combined with Cinnarizine.Approved
ChlorcyclizineThe risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Cinnarizine.Approved
ChloroquineThe risk or severity of QTc prolongation can be increased when Chloroquine is combined with Cinnarizine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Cinnarizine.Approved
ChlorphentermineChlorphentermine may decrease the sedative and stimulatory activities of Cinnarizine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of hypotension can be increased when Chlorpromazine is combined with Cinnarizine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Cinnarizine.Approved, Investigational, Withdrawn
CilostazolThe risk or severity of QTc prolongation can be increased when Cilostazol is combined with Cinnarizine.Approved, Investigational
CimetidineThe serum concentration of Cinnarizine can be increased when it is combined with Cimetidine.Approved, Investigational
CinoxacinThe risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Cinnarizine.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Cinnarizine.Approved, Investigational
CisaprideThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumCinnarizine may increase the neuromuscular blocking activities of Cisatracurium.Approved
CitalopramThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Citalopram.Approved
ClarithromycinThe risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Cinnarizine.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Clemastine.Approved, Investigational
ClomipramineThe risk or severity of QTc prolongation can be increased when Clomipramine is combined with Cinnarizine.Approved, Investigational, Vet Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Cinnarizine.Approved
ClotrimazoleThe metabolism of Cinnarizine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of hypotension can be increased when Clozapine is combined with Cinnarizine.Approved
CobicistatThe metabolism of Cinnarizine can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Cocaine.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Cinnarizine.Approved, Investigational
CrizotinibThe risk or severity of QTc prolongation can be increased when Crizotinib is combined with Cinnarizine.Approved
CUDC-101The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Cinnarizine.Investigational
CUDC-907The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Cinnarizine.Investigational
CurcuminThe metabolism of Cinnarizine can be decreased when combined with Curcumin.Approved, Investigational
CyclizineThe risk or severity of QTc prolongation can be increased when Cyclizine is combined with Cinnarizine.Approved
CyclosporineThe metabolism of Cinnarizine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Cinnarizine.Approved
Cyproterone acetateThe serum concentration of Cinnarizine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Cinnarizine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DanazolThe metabolism of Cinnarizine can be decreased when combined with Danazol.Approved
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Cinnarizine.Approved, Investigational, Withdrawn
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Cinnarizine.Approved
DarunavirThe metabolism of Cinnarizine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Cinnarizine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Cinnarizine can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixThe risk or severity of QTc prolongation can be increased when Degarelix is combined with Cinnarizine.Approved
DelamanidThe risk or severity of QTc prolongation can be increased when Delamanid is combined with Cinnarizine.Approved, Investigational
DelavirdineThe metabolism of Cinnarizine can be decreased when combined with Delavirdine.Approved
DesfluraneThe risk or severity of QTc prolongation can be increased when Desflurane is combined with Cinnarizine.Approved
DesipramineThe risk or severity of QTc prolongation can be increased when Desipramine is combined with Cinnarizine.Approved, Investigational
DesloratadineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Desloratadine.Approved, Investigational
DeutetrabenazineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Deutetrabenazine.Approved, Investigational
DexamethasoneThe serum concentration of Cinnarizine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Cinnarizine.Approved
DexchlorpheniramineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Dexchlorpheniramine.Experimental, Investigational
Dexchlorpheniramine maleateThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Dexchlorpheniramine maleate.Approved
DextroamphetamineDextroamphetamine may decrease the sedative and stimulatory activities of Cinnarizine.Approved, Illicit
DiethylpropionDiethylpropion may decrease the sedative and stimulatory activities of Cinnarizine.Approved, Illicit
DifloxacinThe risk or severity of QTc prolongation can be increased when Difloxacin is combined with Cinnarizine.Vet Approved
DihydroergotamineThe risk or severity of hypotension can be increased when Dihydroergotamine is combined with Cinnarizine.Approved, Investigational
DiltiazemThe metabolism of Cinnarizine can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Cinnarizine.Approved, Investigational
DisopyramideThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Disopyramide.Approved
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Cinnarizine.Approved
DofetilideThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Dofetilide.Approved, Investigational
DolasetronThe risk or severity of QTc prolongation can be increased when Dolasetron is combined with Cinnarizine.Approved, Investigational
DomperidoneThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Domperidone.Approved, Investigational, Vet Approved
DonepezilThe risk or severity of QTc prolongation can be increased when Donepezil is combined with Cinnarizine.Approved
DosulepinThe risk or severity of QTc prolongation can be increased when Dosulepin is combined with Cinnarizine.Approved
DoxacuriumCinnarizine may increase the neuromuscular blocking activities of Doxacurium.Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Cinnarizine.Approved
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Cinnarizine.Approved, Investigational
DoxycyclineThe metabolism of Cinnarizine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineThe risk or severity of QTc prolongation can be increased when Doxylamine is combined with Cinnarizine.Approved, Vet Approved
DronedaroneThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Dronedarone.Approved
DroperidolThe risk or severity of hypotension can be increased when Droperidol is combined with Cinnarizine.Approved, Vet Approved
EbastineThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Cinnarizine.Approved, Investigational
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Cinnarizine.Approved
EfavirenzThe serum concentration of Cinnarizine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Cinnarizine.Approved
EliglustatThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Eliglustat.Approved
EmedastineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Emedastine.Approved
EnoxacinThe risk or severity of QTc prolongation can be increased when Enoxacin is combined with Cinnarizine.Approved, Investigational
EntinostatThe risk or severity of QTc prolongation can be increased when Entinostat is combined with Cinnarizine.Investigational
EnzalutamideThe serum concentration of Cinnarizine can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe risk or severity of QTc prolongation can be increased when Epinastine is combined with Cinnarizine.Approved, Investigational
ErgotamineThe risk or severity of hypotension can be increased when Ergotamine is combined with Cinnarizine.Approved
EribulinThe risk or severity of QTc prolongation can be increased when Eribulin is combined with Cinnarizine.Approved, Investigational
ErlotinibThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Erlotinib.Approved, Investigational
ErythromycinThe risk or severity of QTc prolongation can be increased when Erythromycin is combined with Cinnarizine.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Escitalopram.Approved, Investigational
EtravirineThe serum concentration of Cinnarizine can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of QTc prolongation can be increased when Ezogabine is combined with Cinnarizine.Approved, Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Cinnarizine.Approved
FelbamateThe risk or severity of QTc prolongation can be increased when Felbamate is combined with Cinnarizine.Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Cinnarizine.Experimental
FexofenadineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Fexofenadine.Approved, Investigational
FingolimodThe risk or severity of QTc prolongation can be increased when Fingolimod is combined with Cinnarizine.Approved, Investigational
FlecainideThe risk or severity of QTc prolongation can be increased when Flecainide is combined with Cinnarizine.Approved, Withdrawn
FleroxacinThe risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Cinnarizine.Approved
FluconazoleThe risk or severity of QTc prolongation can be increased when Fluconazole is combined with Cinnarizine.Approved, Investigational
FlumequineThe risk or severity of QTc prolongation can be increased when Flumequine is combined with Cinnarizine.Withdrawn
FluorouracilThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Fluorouracil.Approved
FluoxetineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Flupentixol.Approved, Investigational, Withdrawn
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Cinnarizine.Experimental
FluvoxamineThe metabolism of Cinnarizine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of QTc prolongation can be increased when Formoterol is combined with Cinnarizine.Approved, Investigational
FosamprenavirThe metabolism of Cinnarizine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Cinnarizine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetThe risk or severity of QTc prolongation can be increased when Foscarnet is combined with Cinnarizine.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Cinnarizine.Approved, Investigational
Fusidic AcidThe serum concentration of Cinnarizine can be increased when it is combined with Fusidic Acid.Approved, Investigational
Gadobenic acidThe risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Cinnarizine.Approved, Investigational
GalantamineThe risk or severity of QTc prolongation can be increased when Galantamine is combined with Cinnarizine.Approved
GallamineCinnarizine may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideCinnarizine may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Cinnarizine.Investigational
GatifloxacinThe risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Cinnarizine.Approved, Investigational
GemifloxacinThe risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Cinnarizine.Approved, Investigational
GepefrineGepefrine may decrease the sedative and stimulatory activities of Cinnarizine.Experimental
GivinostatThe risk or severity of QTc prolongation can be increased when Givinostat is combined with Cinnarizine.Investigational
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Cinnarizine.Approved, Investigational
GoserelinThe risk or severity of QTc prolongation can be increased when Goserelin is combined with Cinnarizine.Approved
GranisetronThe risk or severity of QTc prolongation can be increased when Granisetron is combined with Cinnarizine.Approved, Investigational
GrepafloxacinThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Grepafloxacin.Approved, Investigational, Withdrawn
HalofantrineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Halofantrine.Approved
HaloperidolThe risk or severity of QTc prolongation can be increased when Haloperidol is combined with Cinnarizine.Approved
HexobarbitalThe metabolism of Cinnarizine can be increased when combined with Hexobarbital.Approved
HistrelinThe risk or severity of QTc prolongation can be increased when Histrelin is combined with Cinnarizine.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cinnarizine.Approved, Investigational
HydroxyamphetamineHydroxyamphetamine may decrease the sedative and stimulatory activities of Cinnarizine.Approved
HydroxychloroquineThe risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Cinnarizine.Approved
HydroxyzineThe risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Cinnarizine.Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cinnarizine.Approved, Investigational
IbutilideThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Ibutilide.Approved
IdelalisibThe metabolism of Cinnarizine can be decreased when combined with Idelalisib.Approved
IloperidoneThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Iloperidone.Approved
ImatinibThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Imatinib.Approved
ImipramineThe risk or severity of hypotension can be increased when Imipramine is combined with Cinnarizine.Approved
IndacaterolThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Cinnarizine.Approved
IndapamideThe risk or severity of QTc prolongation can be increased when Indapamide is combined with Cinnarizine.Approved
IndinavirThe metabolism of Cinnarizine can be decreased when combined with Indinavir.Approved
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Cinnarizine.Withdrawn
Iofetamine I-123Iofetamine I-123 may decrease the sedative and stimulatory activities of Cinnarizine.Approved
IsavuconazoleThe serum concentration of Cinnarizine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Cinnarizine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Cinnarizine.Approved
IsofluraneThe risk or severity of QTc prolongation can be increased when Isoflurane is combined with Cinnarizine.Approved, Vet Approved
IsoniazidThe metabolism of Cinnarizine can be decreased when combined with Isoniazid.Approved, Investigational
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Cinnarizine.Approved, Investigational
ItraconazoleThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Cinnarizine.Approved, Investigational
IvabradineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Ivabradine.Approved
IvacaftorThe serum concentration of Cinnarizine can be increased when it is combined with Ivacaftor.Approved
IvosidenibThe risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Cinnarizine.Approved, Investigational
KetoconazoleThe risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Cinnarizine.Approved, Investigational
KetotifenThe risk or severity of QTc prolongation can be increased when Ketotifen is combined with Cinnarizine.Approved
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Cinnarizine.Approved
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Cinnarizine.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Cinnarizine.Approved
LapatinibThe risk or severity of QTc prolongation can be increased when Lapatinib is combined with Cinnarizine.Approved, Investigational
LenvatinibThe risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Cinnarizine.Approved, Investigational
LeuprolideThe risk or severity of QTc prolongation can be increased when Leuprolide is combined with Cinnarizine.Approved, Investigational
LevocabastineThe risk or severity of QTc prolongation can be increased when Levocabastine is combined with Cinnarizine.Approved, Investigational
LevocetirizineThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Cinnarizine.Approved
LevofloxacinThe risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Cinnarizine.Approved, Investigational
Levomethadyl AcetateThe risk or severity of QTc prolongation can be increased when Levomethadyl Acetate is combined with Cinnarizine.Approved, Investigational
LidocaineThe metabolism of Cinnarizine can be decreased when combined with Lidocaine.Approved, Vet Approved
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Cinnarizine.Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative and stimulatory activities of Cinnarizine.Approved, Investigational
Lithium cationThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Lithium cation.Experimental
LobeglitazoneThe metabolism of Cinnarizine can be decreased when combined with Lobeglitazone.Approved, Investigational
LomefloxacinThe risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Cinnarizine.Approved, Investigational
LopinavirThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Lopinavir.Approved
LoratadineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Loratadine.Approved, Investigational
LorpiprazoleThe serum concentration of Cinnarizine can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Cinnarizine can be decreased when combined with Lovastatin.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Cinnarizine.Approved, Investigational
LuliconazoleThe serum concentration of Cinnarizine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Cinnarizine can be increased when combined with Lumacaftor.Approved
LumefantrineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Lumefantrine.Approved
MacimorelinThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Macimorelin.Approved, Investigational
Magnesium carbonateThe therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Cinnarizine.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Cinnarizine.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Cinnarizine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Cinnarizine is combined with Magnesium oxide.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Cinnarizine.Experimental
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Cinnarizine is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Cinnarizine is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Cinnarizine.Approved, Investigational
MaprotilineThe risk or severity of QTc prolongation can be increased when Maprotiline is combined with Cinnarizine.Approved, Investigational
MefloquineThe risk or severity of QTc prolongation can be increased when Mefloquine is combined with Cinnarizine.Approved, Investigational
MephedroneMephedrone may decrease the sedative and stimulatory activities of Cinnarizine.Investigational
MephentermineMephentermine may decrease the sedative and stimulatory activities of Cinnarizine.Approved
MepyramineThe risk or severity of QTc prolongation can be increased when Mepyramine is combined with Cinnarizine.Approved, Vet Approved
MequitazineThe risk or severity of QTc prolongation can be increased when Mequitazine is combined with Cinnarizine.Approved
MesoridazineThe risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Cinnarizine.Approved, Investigational
MethadoneThe risk or severity of QTc prolongation can be increased when Methadone is combined with Cinnarizine.Approved
MethamphetamineMethamphetamine may decrease the sedative and stimulatory activities of Cinnarizine.Approved, Illicit
MethohexitalThe metabolism of Cinnarizine can be increased when combined with Methohexital.Approved
MethotrimeprazineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Cinnarizine.Approved, Investigational
MethoxyphenamineMethoxyphenamine may decrease the sedative and stimulatory activities of Cinnarizine.Experimental
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Cinnarizine.Approved
MethylphenobarbitalThe metabolism of Cinnarizine can be increased when combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Cinnarizine.Approved, Investigational
MetocurineCinnarizine may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideCinnarizine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetronidazoleThe risk or severity of QTc prolongation can be increased when Metronidazole is combined with Cinnarizine.Approved
MexiletineThe metabolism of Cinnarizine can be decreased when combined with Mexiletine.Approved, Investigational
MibefradilThe metabolism of Cinnarizine can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Cinnarizine can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MidomafetamineMidomafetamine may decrease the sedative and stimulatory activities of Cinnarizine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Cinnarizine can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Cinnarizine can be increased when it is combined with Mifepristone.Approved, Investigational
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Cinnarizine.Approved, Vet Approved
MirabegronThe risk or severity of QTc prolongation can be increased when Mirabegron is combined with Cinnarizine.Approved
MirtazapineThe risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Cinnarizine.Approved
MitotaneThe serum concentration of Cinnarizine can be decreased when it is combined with Mitotane.Approved
MivacuriumCinnarizine may increase the neuromuscular blocking activities of Mivacurium.Approved
MMDAMMDA may decrease the sedative and stimulatory activities of Cinnarizine.Experimental, Illicit
MocetinostatThe risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Cinnarizine.Investigational
ModafinilThe serum concentration of Cinnarizine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of QTc prolongation can be increased when Moexipril is combined with Cinnarizine.Approved
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Cinnarizine.Approved, Investigational
NafcillinThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Nafcillin.Approved, Investigational
Nalidixic AcidThe risk or severity of QTc prolongation can be increased when Nalidixic Acid is combined with Cinnarizine.Approved, Investigational
NaloxoneThe metabolism of Cinnarizine can be decreased when combined with Naloxone.Approved, Vet Approved
NefazodoneThe risk or severity of hypotension can be increased when Nefazodone is combined with Cinnarizine.Approved, Withdrawn
NelfinavirThe risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Cinnarizine.Approved
NemonoxacinThe risk or severity of QTc prolongation can be increased when Nemonoxacin is combined with Cinnarizine.Investigational
NetupitantThe serum concentration of Cinnarizine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Cinnarizine can be increased when combined with Nevirapine.Approved
NicardipineThe risk or severity of hypotension can be increased when Nicardipine is combined with Cinnarizine.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Cinnarizine.Approved, Investigational
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Cinnarizine.Experimental
NilotinibThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Nilotinib.Approved, Investigational
NitroprussideCinnarizine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NorfloxacinThe risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Cinnarizine.Approved
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Cinnarizine.Approved
OctreotideThe risk or severity of QTc prolongation can be increased when Octreotide is combined with Cinnarizine.Approved, Investigational
OfloxacinThe risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Cinnarizine.Approved
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Cinnarizine.Approved, Investigational
OlaparibThe metabolism of Cinnarizine can be decreased when combined with Olaparib.Approved
OlodaterolThe risk or severity of QTc prolongation can be increased when Olodaterol is combined with Cinnarizine.Approved
OlopatadineThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Cinnarizine.Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Cinnarizine.Experimental
OndansetronThe risk or severity of QTc prolongation can be increased when Ondansetron is combined with Cinnarizine.Approved
OrbifloxacinThe risk or severity of QTc prolongation can be increased when Orbifloxacin is combined with Cinnarizine.Vet Approved
OrphenadrineThe risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Cinnarizine.Approved
OsimertinibThe serum concentration of Cinnarizine can be increased when it is combined with Osimertinib.Approved
OxaliplatinThe risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Cinnarizine.Approved, Investigational
OxatomideThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Oxatomide.Investigational
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Cinnarizine.Approved
Oxolinic acidThe risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Cinnarizine.Experimental
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Cinnarizine.Investigational, Withdrawn
OxytocinThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Cinnarizine.Approved, Vet Approved
PalbociclibThe serum concentration of Cinnarizine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Paliperidone.Approved
PancuroniumCinnarizine may increase the neuromuscular blocking activities of Pancuronium.Approved
PanobinostatThe risk or severity of QTc prolongation can be increased when Panobinostat is combined with Cinnarizine.Approved, Investigational
PapaverineThe risk or severity of QTc prolongation can be increased when Papaverine is combined with Cinnarizine.Approved, Investigational
ParoxetineThe risk or severity of QTc prolongation can be increased when Paroxetine is combined with Cinnarizine.Approved, Investigational
PasireotideThe risk or severity of QTc prolongation can be increased when Pasireotide is combined with Cinnarizine.Approved
Patent BlueThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Patent Blue.Approved
PazopanibThe risk or severity of QTc prolongation can be increased when Pazopanib is combined with Cinnarizine.Approved
PazufloxacinThe risk or severity of QTc prolongation can be increased when Pazufloxacin is combined with Cinnarizine.Investigational
PefloxacinThe risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Cinnarizine.Approved
Peginterferon alfa-2bThe serum concentration of Cinnarizine can be increased when it is combined with Peginterferon alfa-2b.Approved
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Cinnarizine.Experimental
PentamidineThe risk or severity of QTc prolongation can be increased when Pentamidine is combined with Cinnarizine.Approved, Investigational
PentobarbitalThe metabolism of Cinnarizine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerflutrenThe risk or severity of QTc prolongation can be increased when Perflutren is combined with Cinnarizine.Approved
PheniramineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Cinnarizine.Approved
PhenobarbitalThe metabolism of Cinnarizine can be increased when combined with Phenobarbital.Approved, Investigational
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Cinnarizine.Approved, Withdrawn
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Cinnarizine.Approved
PhenterminePhentermine may decrease the sedative and stimulatory activities of Cinnarizine.Approved, Illicit
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Cinnarizine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Cinnarizine.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cinnarizine.Approved
PimozideThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Pimozide.Approved
PipecuroniumCinnarizine may increase the neuromuscular blocking activities of Pipecuronium.Approved
Pipemidic acidThe risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Cinnarizine.Experimental
Piromidic acidThe risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Cinnarizine.Experimental
PitolisantThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Cinnarizine.Approved, Investigational
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Cinnarizine.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Cinnarizine.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Cinnarizine.Approved, Investigational
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Cinnarizine.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Cinnarizine.Approved, Vet Approved
PosaconazoleThe risk or severity of QTc prolongation can be increased when Posaconazole is combined with Cinnarizine.Approved, Investigational, Vet Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Cinnarizine.Approved, Investigational
PracinostatThe risk or severity of QTc prolongation can be increased when Pracinostat is combined with Cinnarizine.Investigational
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Cinnarizine.Approved
PrimaquineThe risk or severity of QTc prolongation can be increased when Primaquine is combined with Cinnarizine.Approved
PrimidoneThe metabolism of Cinnarizine can be increased when combined with Primidone.Approved, Vet Approved
ProbucolThe risk or severity of QTc prolongation can be increased when Probucol is combined with Cinnarizine.Approved, Investigational
ProcainamideThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Procainamide.Approved
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Cinnarizine.Approved, Vet Approved
PromethazineThe risk or severity of QTc prolongation can be increased when Promethazine is combined with Cinnarizine.Approved, Investigational
PropafenoneThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Cinnarizine.Approved
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Cinnarizine.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Cinnarizine.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Cinnarizine.Approved, Investigational
PropofolThe risk or severity of QTc prolongation can be increased when Propofol is combined with Cinnarizine.Approved, Investigational, Vet Approved
ProtriptylineThe risk or severity of QTc prolongation can be increased when Protriptyline is combined with Cinnarizine.Approved
PrucaloprideThe therapeutic efficacy of Prucalopride can be decreased when used in combination with Cinnarizine.Approved
PrulifloxacinThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Cinnarizine.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative and stimulatory activities of Cinnarizine.Approved
QuetiapineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Quetiapine.Approved
QuinidineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Quinidine.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Quinine.Approved
RanolazineThe risk or severity of QTc prolongation can be increased when Ranolazine is combined with Cinnarizine.Approved, Investigational
RapacuroniumCinnarizine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RavuconazoleThe therapeutic efficacy of Ravuconazole can be increased when used in combination with Cinnarizine.Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Ribociclib.Approved, Investigational
RicolinostatThe risk or severity of QTc prolongation can be increased when Ricolinostat is combined with Cinnarizine.Investigational
RifampicinThe metabolism of Cinnarizine can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Cinnarizine can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Cinnarizine can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Cinnarizine can be increased when combined with Rifaximin.Approved, Investigational
RilpivirineThe risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Cinnarizine.Approved
RimexoloneThe metabolism of Cinnarizine can be increased when combined with Rimexolone.Approved
RisperidoneThe risk or severity of hypotension can be increased when Risperidone is combined with Cinnarizine.Approved, Investigational
RitobegronRitobegron may decrease the sedative and stimulatory activities of Cinnarizine.Investigational
RitonavirThe risk or severity of QTc prolongation can be increased when Ritonavir is combined with Cinnarizine.Approved, Investigational
RocuroniumCinnarizine may increase the neuromuscular blocking activities of Rocuronium.Approved
RomidepsinThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Romidepsin.Approved, Investigational
RopiniroleThe metabolism of Cinnarizine can be decreased when combined with Ropinirole.Approved, Investigational
RosoxacinThe risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Cinnarizine.Approved, Investigational
RoxithromycinThe risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Cinnarizine.Approved, Investigational, Withdrawn
RufloxacinThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Cinnarizine.Experimental
RupatadineThe risk or severity of QTc prolongation can be increased when Rupatadine is combined with Cinnarizine.Approved
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Cinnarizine.Approved, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Cinnarizine.Approved
SaquinavirThe risk or severity of QTc prolongation can be increased when Saquinavir is combined with Cinnarizine.Approved, Investigational
SarafloxacinThe risk or severity of QTc prolongation can be increased when Sarafloxacin is combined with Cinnarizine.Vet Approved, Withdrawn
SarilumabThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Sarilumab.Approved, Investigational
SecobarbitalThe metabolism of Cinnarizine can be increased when combined with Secobarbital.Approved, Vet Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Cinnarizine.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Cinnarizine.Approved, Investigational
SertralineThe risk or severity of QTc prolongation can be increased when Sertraline is combined with Cinnarizine.Approved
SevofluraneThe risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Cinnarizine.Approved, Vet Approved
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Cinnarizine.Approved
SiltuximabThe serum concentration of Cinnarizine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Cinnarizine can be increased when it is combined with Simeprevir.Approved
SitafloxacinThe risk or severity of QTc prolongation can be increased when Sitafloxacin is combined with Cinnarizine.Experimental, Investigational
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Cinnarizine.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Cinnarizine.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Cinnarizine.Approved
SolifenacinThe risk or severity of QTc prolongation can be increased when Solifenacin is combined with Cinnarizine.Approved
SorafenibThe risk or severity of QTc prolongation can be increased when Sorafenib is combined with Cinnarizine.Approved, Investigational
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Cinnarizine.Approved
SotalolThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Sotalol.Approved
SparfloxacinThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Sparfloxacin.Approved, Investigational
St. John's WortThe serum concentration of Cinnarizine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Cinnarizine can be increased when it is combined with Stiripentol.Approved
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Cinnarizine.Approved
SulfamethoxazoleThe risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Cinnarizine.Approved
SulfisoxazoleThe risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Cinnarizine.Approved, Vet Approved
SulpirideThe risk or severity of QTc prolongation can be increased when Sulpiride is combined with Cinnarizine.Approved, Investigational
SultoprideThe risk or severity of QTc prolongation can be increased when Sultopride is combined with Cinnarizine.Experimental
SunitinibThe risk or severity of QTc prolongation can be increased when Sunitinib is combined with Cinnarizine.Approved, Investigational
TamoxifenThe risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Cinnarizine.Approved
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Cinnarizine.Approved, Investigational
TandutinibThe risk or severity of QTc prolongation can be increased when Tandutinib is combined with Cinnarizine.Investigational
Technetium Tc-99m ciprofloxacinThe risk or severity of QTc prolongation can be increased when Technetium Tc-99m ciprofloxacin is combined with Cinnarizine.Investigational
TegaserodThe therapeutic efficacy of Tegaserod can be decreased when used in combination with Cinnarizine.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Cinnarizine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinThe risk or severity of QTc prolongation can be increased when Telavancin is combined with Cinnarizine.Approved
TelithromycinThe risk or severity of QTc prolongation can be increased when Telithromycin is combined with Cinnarizine.Approved
TemafloxacinThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Temafloxacin.Withdrawn
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Cinnarizine.Approved
TerbutalineThe risk or severity of QTc prolongation can be increased when Terbutaline is combined with Cinnarizine.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Cinnarizine.Approved
TerfenadineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Terfenadine.Approved, Withdrawn
TeriflunomideThe serum concentration of Cinnarizine can be decreased when it is combined with Teriflunomide.Approved
TerlipressinThe risk or severity of QTc prolongation can be increased when Terlipressin is combined with Cinnarizine.Approved, Investigational
TerodilineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Terodiline.Experimental
TetrabenazineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Tetrabenazine.Approved, Investigational
TheophyllineThe metabolism of Cinnarizine can be decreased when combined with Theophylline.Approved
ThiamylalThe metabolism of Cinnarizine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Cinnarizine can be increased when combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Cinnarizine.Approved
ThioridazineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of QTc prolongation can be increased when Thiothixene is combined with Cinnarizine.Approved
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Cinnarizine.Approved
TipranavirThe metabolism of Cinnarizine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of QTc prolongation can be increased when Tizanidine is combined with Cinnarizine.Approved, Investigational
TocilizumabThe serum concentration of Cinnarizine can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Cinnarizine.Approved, Vet Approved
TolterodineThe risk or severity of QTc prolongation can be increased when Tolterodine is combined with Cinnarizine.Approved, Investigational
ToremifeneThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Toremifene.Approved, Investigational
TrazodoneThe risk or severity of hypotension can be increased when Trazodone is combined with Cinnarizine.Approved, Investigational
TreprostinilThe risk or severity of QTc prolongation can be increased when Treprostinil is combined with Cinnarizine.Approved, Investigational
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Cinnarizine.Approved, Investigational
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Cinnarizine.Experimental
TrimethoprimThe risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Cinnarizine.Approved, Vet Approved
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Cinnarizine.Approved
TriprolidineThe risk or severity of QTc prolongation can be increased when Triprolidine is combined with Cinnarizine.Approved
TriptorelinThe risk or severity of QTc prolongation can be increased when Triptorelin is combined with Cinnarizine.Approved, Vet Approved
TroleandomycinThe metabolism of Cinnarizine can be decreased when combined with Troleandomycin.Approved
TrovafloxacinThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineCinnarizine may increase the neuromuscular blocking activities of Tubocurarine.Approved
TucidinostatThe risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Cinnarizine.Investigational
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Cinnarizine.Investigational
Valproic AcidThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Valproic Acid.Approved, Investigational
VandetanibThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Vandetanib.Approved
VardenafilThe risk or severity of QTc prolongation can be increased when Vardenafil is combined with Cinnarizine.Approved
VecuroniumCinnarizine may increase the neuromuscular blocking activities of Vecuronium.Approved
VenlafaxineThe risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Cinnarizine.Approved
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Cinnarizine.Approved
VilanterolThe risk or severity of QTc prolongation can be increased when Vilanterol is combined with Cinnarizine.Approved
VoriconazoleThe risk or severity of QTc prolongation can be increased when Voriconazole is combined with Cinnarizine.Approved, Investigational
VorinostatThe risk or severity of QTc prolongation can be increased when Vorinostat is combined with Cinnarizine.Approved, Investigational
ZafirlukastThe metabolism of Cinnarizine can be decreased when combined with Zafirlukast.Approved, Investigational
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Ziprasidone.Approved
ZucapsaicinThe metabolism of Cinnarizine can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Janssen, P.A.J.; U.S. Patent 2,882,271; April 14, 1959; assigned to Laboratoria Pharmaceutica Dr. C. Janssen, Belgium.

General References
Not Available
External Links
KEGG Drug
D01295
PubChem Compound
2761
PubChem Substance
46506769
ChemSpider
1264793
BindingDB
50017657
ChEBI
31403
ChEMBL
CHEMBL43064
Therapeutic Targets Database
DAP000325
PharmGKB
PA164749342
Wikipedia
Cinnarizine
ATC Codes
N07CA52 — Cinnarizine, combinationsN07CA02 — Cinnarizine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentMethamphetamine-induced Psychosis1
Not AvailableUnknown StatusPreventionSimulator Sickness1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility750 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP5.77BIOBYTE (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.00172 mg/mLALOGPS
logP5.19ALOGPS
logP5.88ChemAxon
logS-5.3ALOGPS
pKa (Strongest Basic)8.4ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity119.86 m3·mol-1ChemAxon
Polarizability43.96 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9506
Blood Brain Barrier+0.977
Caco-2 permeable+0.6409
P-glycoprotein substrateSubstrate0.7107
P-glycoprotein inhibitor IInhibitor0.7461
P-glycoprotein inhibitor IINon-inhibitor0.8398
Renal organic cation transporterInhibitor0.7902
CYP450 2C9 substrateNon-substrate0.8549
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.7558
CYP450 1A2 substrateInhibitor0.7732
CYP450 2C9 inhibitorNon-inhibitor0.9488
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9346
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5
Ames testNon AMES toxic0.9279
CarcinogenicityNon-carcinogens0.9496
BiodegradationNot ready biodegradable0.9968
Rat acute toxicity2.0618 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5724
hERG inhibition (predictor II)Non-inhibitor0.524
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Styrenes / N-alkylpiperazines / Aralkylamines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Diphenylmethane / Styrene / Aralkylamine / N-alkylpiperazine / 1,4-diazinane / Piperazine / Tertiary amine / Tertiary aliphatic amine / Azacycle / Organoheterocyclic compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Paton DM, Webster DR: Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet. 1985 Nov-Dec;10(6):477-97. [PubMed:2866055]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1C
Uniprot ID
Q13936
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight
248974.1 Da
References
  1. Singh BN: The mechanism of action of calcium antagonists relative to their clinical applications. Br J Clin Pharmacol. 1986;21 Suppl 2:109S-121S. [PubMed:3530295]
  2. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1D
Uniprot ID
Q01668
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1D
Molecular Weight
245138.75 Da
References
  1. Singh BN: The mechanism of action of calcium antagonists relative to their clinical applications. Br J Clin Pharmacol. 1986;21 Suppl 2:109S-121S. [PubMed:3530295]
  2. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1F
Uniprot ID
O60840
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1F
Molecular Weight
220675.9 Da
References
  1. Singh BN: The mechanism of action of calcium antagonists relative to their clinical applications. Br J Clin Pharmacol. 1986;21 Suppl 2:109S-121S. [PubMed:3530295]
  2. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1S
Uniprot ID
Q13698
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1S
Molecular Weight
212348.1 Da
References
  1. Singh BN: The mechanism of action of calcium antagonists relative to their clinical applications. Br J Clin Pharmacol. 1986;21 Suppl 2:109S-121S. [PubMed:3530295]
  2. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1G
Uniprot ID
O43497
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1G
Molecular Weight
262468.62 Da
References
  1. Singh BN: The mechanism of action of calcium antagonists relative to their clinical applications. Br J Clin Pharmacol. 1986;21 Suppl 2:109S-121S. [PubMed:3530295]
  2. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1H
Uniprot ID
O95180
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1H
Molecular Weight
259160.2 Da
References
  1. Singh BN: The mechanism of action of calcium antagonists relative to their clinical applications. Br J Clin Pharmacol. 1986;21 Suppl 2:109S-121S. [PubMed:3530295]
  2. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1I
Uniprot ID
Q9P0X4
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1I
Molecular Weight
245100.8 Da
References
  1. Singh BN: The mechanism of action of calcium antagonists relative to their clinical applications. Br J Clin Pharmacol. 1986;21 Suppl 2:109S-121S. [PubMed:3530295]
  2. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Other/unknown
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Brucke T, Wober C, Podreka I, Wober-Bingol C, Asenbaum S, Aull S, Wenger S, Ilieva D, Harasko-van der Meer C, Wessely P, et al.: D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study. J Cereb Blood Flow Metab. 1995 May;15(3):513-8. [PubMed:7714010]
  2. Kuzuhara S: [Drug-induced parkinsonism]. Nihon Rinsho. 1997 Jan;55(1):112-7. [PubMed:9014432]
  3. doi:10.1007/s00415-006-3004-8 [Link]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.

Components:
References
  1. Nasu R, Matsuo H, Takanaga H, Ohtani H, Sawada Y: Quantitative prediction of catalepsy induced by amoxapine, cinnarizine and cyclophosphamide in mice. Biopharm Drug Dispos. 2000 May;21(4):129-38. [PubMed:11180191]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...

Components:
References
  1. Nasu R, Matsuo H, Takanaga H, Ohtani H, Sawada Y: Quantitative prediction of catalepsy induced by amoxapine, cinnarizine and cyclophosphamide in mice. Biopharm Drug Dispos. 2000 May;21(4):129-38. [PubMed:11180191]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Uesawa Y, Takeuchi T, Mohri K: Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17. [PubMed:22039822]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 04:23